Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
At $84000 Gilead Hepatitis C Drug Sets Off Payer Revolt

Gilead’s new drug, Sovaldi, costs $84,000 for a 12-week treatment. Such breakthrough treatments and their stratospheric price tags have “absolutely” caused insurers to reconsider covering high-priced hepatitis, diabetes and other treatments, said Sumit Dutta, chief medical officer of Catamaran, the fourth-biggest U.S. pharmacy benefit manager, or PBM.

Published
27 January 2014
From
Bloomberg
Only just the beginning of the end of hepatitis C

The main drawback of these new agents is the huge price tag, which will make treatment out of reach for people in the developed and developing world. The other concern is the limited testing of these new treatments on less common genotypes and marginalised populations disproportionately affected by HCV infection. For example, there has been minimal testing among those co-infected with HIV.

Published
26 January 2014
From
The Lancet (editorial)
Hep C drug deleobuvir pulled from clinical study, citing high rate of early discontinuations

Following an assessment of the blinded Phase 3 trial data from HCVerso 1 and 2 for the combination of deleobuvir, faldaprevir and ribavirin, Boehringer Ingelheim has decided to halt further development of deleobuvir-containing hepatitis C (HCV) regimens.

Published
21 January 2014
From
Project Inform
European Commission Grants Marketing Authorization for Gilead’s Sovaldi® (Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection

Sofosbuvir has been approved for hepatitis C treatment in genotypes 1-6.

Published
17 January 2014
From
Gilead press release
Bristol-Myers Ties Hepatitis C Success to Gilead’s Pill

Bristol-Myers Squibb Co. will try to grab an early share of the multibillion-dollar market for new hepatitis C treatments by piggybacking its experimental drug with Gilead Sciences Inc.’s approved pill.

Published
14 January 2014
From
Bloomberg
What Is a Hepatitis C Drug Worth?

The founder of the company that discovered the Sovaldi hepatitis C drug, which has been listed with a cost of $1,000 for a single pill, says that it’s fairly cheap to make the basic ingredients for this well-regarded new medicine. It may cost only about $1,400 to manufacture a 12-week supply, or 84 pills.

Published
14 January 2014
From
Roll Call
Achillion Reports HCV Pipeline Progress and Outlines 2014 HCV Milestones

Achillion anticipates the initiation of an all-oral Phase 2 combination study evaluating ACH-3422 by year-end 2014, and anticipates the initiation of a Phase 2 combination study evaluating ACH-3422 and ACH-3102, with and without an Achillion NS3/4A protease inhibitor, in treatment-naive HCV patients over treatment durations of 8 weeks or less in early 2015.

Published
14 January 2014
From
Achillion press release
Vertex Announces Sustained Viral Response Rate (SVR4) Data from All-Oral Study of VX-135 in Combination with Daclatasvir in Hepatitis C

In an intent-to-treat analysis, the sustained viral response rate four weeks after the completion of treatment (SVR4) was 83 percent (10 of 12) in treatment-naive genotype 1 patients who received 200 mg of VX-135 in combination with daclatasvir.

Published
09 January 2014
From
Vertex press release
Daclatasvir Marketing Authorization Application for Treatment of Chronic Hepatitis C Validated for Accelerated Regulatory Review by the European Medicines Agency

The application seeks the approval of daclatasvir for use in combination with other agents, including sofosbuvir, for the treatment of chronic hepatitis C genotypes 1, 2, 3 and 4.

Published
08 January 2014
From
Bristol-Myers Squibb press release
$1000 Pill For Hepatitis C Spurs Debate Over Drug Prices

Some activists are beginning to complain about Gilead's decision to charge so much for sofosbuvir.

Published
06 January 2014
From
NPR (blog)

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.